Increased levels of proneurotensin/neuromedin N mRNA in rat striatum and nucleus accumbens induced by 7-OH-DPAT and nafadotride

Neuropsychopharmacology

Volumn 21, Issue 2, 1999, Pages 304-311

  Levant, Beth ^a   Garimelli, Bina ^b   Shafer, Rose A ^a   Merchant, Kalpana M ^c  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b WESTERN MICHIGAN UNIVERSITY   (United States)

^c PFIZER INC   (United States)

Author keywords

7 OH DPAT; D3 dopamine receptor; Nafadotride; Neurotensin; Nucleus accumbens; Striatum

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; DOPAMINE 3 RECEPTOR; HALOPERIDOL; MESSENGER RNA; NAFADOTRIDE; NEUROMEDIN N; NEUROTENSIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; GENE EXPRESSION; HISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR DENSITY; RECEPTOR OCCUPANCY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; CORPUS STRIATUM; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; GENE EXPRESSION REGULATION; HALOPERIDOL; MALE; NAPHTHALENES; NEUROTENSIN; NUCLEUS ACCUMBENS; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; TETRAHYDRONAPHTHALENES; TRANSCRIPTION, GENETIC;

EID: 0033045707     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00033-0     Document Type: Article

References (40)

1. 3-selective ligand 7-OH-DPAT in the normal and reserpine-treated rat. Eur. J. Pharmacol. 260:1994;171-181.
2. 3 dopamine receptor, in rat brain. A receptor binding and quantitative autoradiographic study Neuro psychopharmacology. 18:1998;305-316.
3. 2 receptor mRNA Brain Res. 564:1991;203-219.
4. Chesselet M.-F., Weiss-Wunder L.T. Quantification of in situ hybridization histochemistry. Eberwine J.H., Valentino K.L., Barchas J.D. In Situ Hybridization in Neurobiology. 1994;114-123 Oxford University Press, New York.
5. Dall S., Gandolfi O., Vaccheri A., Roncada P., Montanaro N. Changes in behavioral responses to the combined administration of D1 and D2 dopamine agonists in normosensitive and D1 supersensitive rats. Psychopharmacology. 95:1988;81-385.
6. Daly S.A., Waddington J.L. Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other "D-2-like" agonists. Neuropharmacology. 32:1993;509-510.
7. Diaz J., Lévesque D., Griffon N., Lammers C.H., Martres M.P., Sokoloff P., Schwartz J.C. Opposing roles for dopamine D2 and D3 receptors on neurotensin mRNA expression in nucleus accumbens. Eur J Neurosci. 6:1994;1384-1387.
8. Eilam D., Szechtman H. Biphasic effect of D-2 agonist quinpirole on locomotion and movements. Eur J Pharmacol. 161:1989;151-157.
9. Elliott P.J., Chan J., Parker Y.-M., Nemeroff C.B. Behavioral effects of neurotensin in the open field. Structure-activity studies Brain Res. 381:1986;259-265.
10. Gerlach J. New antipsychotics. Classification, efficacy, and adverse effects Schizophr Bull. 17:1991;289-309.
11. Govoni S., Hong J.S., Yang H.-T., Costa E. Increase of neurotensin content elicited by neuroleptics in nucleus accumbens. J Pharmacol Exp Ther. 215:1980;413-417.
12. 3-preferring agonist 7-OH-DPAT on motor behaviors and place conditioning. Psychopharmacology. 122:1995;351-357.
13. Kilts C.D., Anderson C.M., Bissette G., Ely T.D., Nemeroff C.B. Differential effects of antipsychotic drugs on the neurotensin concentration of discrete brain nuclei. Biochem Pharmacol. 37:1988;1547-1554.
14. 3 receptor mutant mice. J Neurosci. 18:1998;2231-2238.
15. 3 dopamine receptor. Neurobiology and potential clinical relevance Pharmacol Rev. 49:1997;231-252.
16. 3 dopamine receptors in the brains of several mammalian species. Brain Res. 800:1998;269-274.
17. Levant B., Nemeroff C.B. Sigma Receptor "antagonist" BMY 14802 increases neurotensin concentrations in the rat nucleus accumbens and caudate. J Pharmacol Exp Ther. 254:1990;330-335.
18. 2 dopamine receptors by 7-OH-DPAT. Synapse. 24:1996;60-64.
19. Levant B., Bissette G., Davis M.D., Heffner T.G., Nemeroff C.B. Effects of CI-943, a potential drug, and haloperidol on regional brain neurotensin concentrations. Synapse. 9:1991;225-230. a.
20. Levant B., Bissette G., Widerlöv E., Nemeroff C.B. Alterations in regional brain neurotensin concentrations produced by atypical antipsychotic drugs. Regul Peptides. 32:1991;193-202. b.
21. Levant B., Merchant K.M., Dorsa D.M., Nemeroff C.B. BMY 14802, a potential antipsychotic drug, increases expression of proneurotensin mRNA in the rat striatum. Brain Res Mol Brain Res. 12:1992;279-284.
22. Levant B., Vansell N.R. In vivo occupancy of D2 dopamine receptors by nafadotride. Neuropsychopharmacology. 17:1997;67-71.
23. 2 receptor occupation by typical and atypical antipsychotic drugs in vivo. J Pharmacol Exp Ther. 265:1993;498-508.
24. Merchant K.M. c-fos antisense oligonucleotide specifically attenuates haloperidol-induced increases in neurotensin/neuromedin N mRNA expression in rat dorsal striatum. Mol Cell Neurosci. 5:1994;336-344.
25. Merchant K.M., Dobie D.J., Dorsa D.M. Expression of the proneurotensin gene in the rat brain and its regulation by antipsychotic drugs. Ann N Y Acad Sci. 668:1992;54-69. a.
26. Merchant K.M., Dobie D.J., Filloux F.M., Totzke M., Aravagiri M., Dorsa D.M. Effects of chronic haloperidol and clozapine treatment on neurotensin and c-fos mRNA in rat neostriatal subregions. J Pharmacol Exp Ther. 271:1994;460-471. a.
27. Merchant K.M., Dobner P.R., Dorsa D.M. Differential effects of haloperidol and clozapine on neurotensin gene transcription in rat neostriatum. J Neurosci. 12:1992;652-663. b.
28. Merchant K.M., Dorsa D.M. Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics. Proc Natl Acad Sci U S A. 90:1993;3447-3451.
29. Merchant K.M., Gibb J.W., Hanson G.R. Role of dopamine D-1 and D-2 receptors in the regulation of neurotensin systems of the neostriatum and the nucleus accumbens. Eur J Pharmacol. 160:1989;409-412.
30. Merchant K.M., Hanson G.R., Dorsa D.M. Induction of neurotensin and c-fos mRNA in distinct subregions of rat neostriatum after acute methamphetamine. comparison with acute haloperidol effects J Pharmacol Exp Ther. 269:1994;806-812. b.
31. Merchant K.M., Letter A.A., Johnson M., Stone D.M., Gibb J.W., Hanson G.R. Effects of amphetamine analogs on neurotensin concentrations in rat brain. Eur J Pharmacol. 138:1987;151-154.
32. Merchant K.M., Miller M.A., Ashleigh E.A., Dorsa D.M. Haloperidol rapidly increases the number of neurotensin mRNA-expressing neurons in neostriatum of the rat brain. Brain Res. 540:1991;311-314.
33. Nemeroff C.B., Levant B., Myers B., Bissette G. Neurotensin, antipsychotic drugs and schizophrenia. Basic and clinical studies Ann NY Acad Sci. 668:1992;146-156.
34. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, Sydney, Australia.
35. Rinkel G.J.E., Hoeke E.C., van Wimersma-Greidanus T.J.B. Elective tolerance to the behavioral effects of neurotensin. Pharmacol Behav. 31:1983;467-470.
36. 3 receptor antagonist, activates locomotion in rodents. J Pharmacol Exp Ther. 275:1995;1239-1246.
37. Seeman P. Brain Dopamine Receptors. Pharmacological Rev. 32:1981;229-313.
38. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 347:1990;146-151.
39. Stevens J.R. An anatomy of schizophrenia? Arch Gen Psychiatry. 29:1973;177-189.
40. 3 antisense reduces neuropeptide mRNA levels in rat nucleus accumbens. NeuroReport. 8:1997;3901-3905.